within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EX14_Entrectinib;

model Entrectinib
  extends Pharmacolibrary.Drugs.ATC.L.L01EX14;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>L01EX14</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Entrectinib is an orally administered, selective tyrosine kinase inhibitor targeting TRKA, TRKB, TRKC, ROS1, and ALK. It is primarily indicated for the treatment of solid tumors with NTRK gene fusions and ROS1-positive non-small cell lung cancer (NSCLC). Entrectinib is approved for clinical use in several countries, including the US and EU.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetic parameters reported for adult patients with solid tumors following oral administration.</p><h4>References</h4><ol><li><p>Meneses-Lorente, G, Bentley, D, Guerini, E, Kowalski, K, Chow-Maneval, E, Yu, L, Brink, A, Djebli, N, Mercier, F, Buchheit, V, &amp; Phipps, A (2021). Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. <i>Investigational new drugs</i> 39(3) 803–811. DOI:<a href=&quot;https://doi.org/10.1007/s10637-020-01047-5&quot;>10.1007/s10637-020-01047-5</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/33462752/&quot;>https://pubmed.ncbi.nlm.nih.gov/33462752</a></p></li><li><p>Drilon, A, Siena, S, Ou, SI, Patel, M, Ahn, MJ, Lee, J, Bauer, TM, Farago, AF, Wheler, JJ, Liu, SV, Doebele, R, Giannetta, L, Cerea, G, Marrapese, G, Schirru, M, Amatu, A, Bencardino, K, Palmeri, L, Sartore-Bianchi, A, …, &amp; De Braud, FG (2017). Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1). <i>Cancer discovery</i> 7(4) 400–409. DOI:<a href=&quot;https://doi.org/10.1158/2159-8290.CD-16-1237&quot;>10.1158/2159-8290.CD-16-1237</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/28183697/&quot;>https://pubmed.ncbi.nlm.nih.gov/28183697</a></p></li><li><p>Jiang, Q, Li, M, Li, H, &amp; Chen, L (2022). Entrectinib, a new multi-target inhibitor for cancer therapy. <i>Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie</i> 150 112974–None. DOI:<a href=&quot;https://doi.org/10.1016/j.biopha.2022.112974&quot;>10.1016/j.biopha.2022.112974</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/35447552/&quot;>https://pubmed.ncbi.nlm.nih.gov/35447552</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Entrectinib;
